Fabrice Egros - 18 Aug 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
18 Aug 2021
Net transactions value
-$123,124
Form type
4
Filing time
20 Aug 2021, 16:32:17 UTC
Previous filing
20 May 2021
Next filing
19 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $123,204 +15,635 +98% $7.88 31,635 18 Aug 2021 Direct
transaction SNDX Common Stock Sale $246,328 -15,635 -49% $15.75 16,000 18 Aug 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -15,635 -100% $0.000000* 0 18 Aug 2021 Common Stock 0 $7.88 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 77,682 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $15.58 to $15.94.
F3 This option is fully vested.